Key facts
- Rune Labs’s last known valuation is $24.7M (Jun 2025).
- It has raised $57.4M across 6 recorded rounds; the latest was Early Stage VC ($11.2M) in Jun 2025.
- Notable investors include Samsung NEXT Ventures, 468 Capital, Village Global, City Light Capital, Eclipse Capital — 16 tracked in total.
- Rune Labs has filed 6 Form Ds with the SEC since 2019, most recently Jun 2025 ($11.2M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Rune Labs
Funding rounds
6 roundsAbout Rune Labs
Developer of a medical platform designed to integrate with neuromodulation therapies to manage data ingestion, labelling, and availability. The company's software platform helps partners in med-tech and pharma to ingest, organize, and analyze large amounts of brain input and output data, all on state-of-the-art secure cloud infrastructure, enabling clients to utilize data from new sensing and stim neuromodulation devices for therapy development and clinical and commercial closed-loop and adaptive therapy applications.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 58
- Website
- runelabs.io/
- Ownership
- Privately Held (backing)
Rune Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rune Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rune Labs in its N-PORT filings yet. We sweep new filings monthly.